Stoke Therapeutics, Inc. (STOK)
25.04
-0.66
(-2.57%)
USD |
NASDAQ |
Oct 23, 16:00
25.03
-0.01
(-0.04%)
After-Hours: 20:00
Stoke Therapeutics Profit Margin (Quarterly) : -660.8% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -660.8% |
| March 31, 2026 | -802.7% |
| December 31, 2025 | -4.13K% |
| September 30, 2025 | -360.7% |
| June 30, 2025 | -170.0% |
| March 31, 2025 | 71.19% |
| December 31, 2024 | -46.36% |
| September 30, 2024 | -540.0% |
| June 30, 2024 | -531.9% |
| Date | Value |
|---|---|
| March 31, 2024 | -625.6% |
| December 31, 2023 | -962.1% |
| September 30, 2023 | -741.9% |
| June 30, 2023 | |
| March 31, 2023 | -437.6% |
| December 31, 2022 | -784.8% |
| September 30, 2022 | -898.8% |
| June 30, 2022 | -763.0% |
| March 31, 2022 | -821.6% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | -1.64% |
| Amgen, Inc. | 23.59% |
| Anika Therapeutics, Inc. | 10.15% |
| BioCryst Pharmaceuticals, Inc. | 35.92% |
| Imunon, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -59.88% |
| Return on Assets | -51.96% |
| Return on Invested Capital | -59.25% |
| Gross Profit Margin (Quarterly) | 87.80% |
| Operating Margin (Quarterly) | -701.7% |
| Return on Net Operating Assets | -912.0% |